Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer
Youngjoo Lee, Ki Hyeong Lee, Geon Kook Lee, Soo-Hyun Lee, Kun Young Lim, Jungnam Joo, Yun Jung Go, Jin Soo Lee, Ji-Youn Han
Cancer Res Treat. 2017;49(4):1001-1011.   Published online 2017 Jan 13     DOI: https://doi.org/10.4143/crt.2016.546
Citations to this article as recorded by Crossref logo
Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs
Kush K. Patel, Khosrow Kashfi
Biochemical Pharmacology.2022; 196: 114654.     CrossRef
Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer
Yoichi Morofuji, Shinsuke Nakagawa, Kenta Ujifuku, Takashi Fujimoto, Kaishi Otsuka, Masami Niwa, Keisuke Tsutsumi
Pharmaceuticals.2022; 15(2): 151.     CrossRef
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer
Kamal Eltayeb, Silvia La Monica, Marcello Tiseo, Roberta Alfieri, Claudia Fumarola
Cells.2022; 11(3): 413.     CrossRef
Effect of Statins on Lung Cancer Molecular Pathways: A Possible Therapeutic Role
Gianmarco Marcianò, Caterina Palleria, Alessandro Casarella, Vincenzo Rania, Emanuele Basile, Luca Catarisano, Cristina Vocca, Luigi Bianco, Corrado Pelaia, Erika Cione, Bruno D’Agostino, Rita Citraro, Giovambattista De Sarro, Luca Gallelli
Pharmaceuticals.2022; 15(5): 589.     CrossRef
Lipid metabolism and cancer
Xueli Bian, Rui Liu, Ying Meng, Dongming Xing, Daqian Xu, Zhimin Lu
Journal of Experimental Medicine.2021;[Epub]     CrossRef
Simvastatin-romidepsin combination kills bladder cancer cells synergistically
Kazuki Okubo, Kosuke Miyai, Kimi Kato, Takako Asano, Akinori Sato
Translational Oncology.2021; 14(9): 101154.     CrossRef
Statins Decrease Programmed Death-Ligand 1 (PD-L1) by Inhibiting AKT and β-Catenin Signaling
Woo-Jin Lim, Mingyu Lee, Yerin Oh, Xue-Quan Fang, Sujin Lee, Chang-Hoon Lim, Jooho Park, Ji-Hong Lim
Cells.2021; 10(9): 2488.     CrossRef
ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells
Jillian Hattaway Luttman, Jacob P. Hoj, Kevin H. Lin, Jiaxing Lin, Jing Jin Gu, Clay Rouse, Amanda G. Nichols, Nancie J. MacIver, Kris C. Wood, Ann Marie Pendergast
Cell Reports.2021; 37(4): 109880.     CrossRef
Adjuvant statin therapy for oesophageal adenocarcinoma: the STAT-ROC feasibility study
L. Alexandre, A. B. Clark, S. Walton, M. P. Lewis, B. Kumar, E. C. Cheong, H. Warren, S. S. Kadirkamanathan, S. L. Parsons, S. M. Dresner, E. Sims, M. Jones, M. Hammond, M. Flather, Y. K. Loke, A. M. Swart, A. R. Hart
BJS Open.2020; 4(1): 59.     CrossRef
Whether statin use improves the survival of patients with glioblastoma?
Yonglin Xie, Qin Lu, Cameron Lenahan, Shuxu Yang, Daoyang Zhou, Xuchen Qi
Medicine.2020; 99(9): e18997.     CrossRef
Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells
Kazuki Okubo, Makoto Isono, Kosuke Miyai, Takako Asano, Akinori Sato
Cancer Science.2020; 111(1): 112.     CrossRef
Repurposing of drugs approved for cardiovascular diseases: Opportunity or mirage?
Paolo Gelosa, Laura Castiglioni, Marina Camera, Luigi Sironi
Biochemical Pharmacology.2020; 177: 113895.     CrossRef
Attenuation of the pro-inflammatory signature of lung cancer-derived mesenchymal stromal cells by statins
Sabine Galland, Patricia Martin, Giulia Fregni, Igor Letovanec, Ivan Stamenkovic
Cancer Letters.2020; 484: 50.     CrossRef
Efficacy and safety profile of statins in patients with cancer: a systematic review of randomised controlled trials
John P. Thomas, Yoon K. Loke, Leo Alexandre
European Journal of Clinical Pharmacology.2020; 76(12): 1639.     CrossRef
Statins as Anticancer Agents in the Era of Precision Medicine
Joseph Longo, Jenna E. van Leeuwen, Mohamad Elbaz, Emily Branchard, Linda Z. Penn
Clinical Cancer Research.2020; 26(22): 5791.     CrossRef
Dipyridamole Enhances the Cytotoxicities of Trametinib against Colon Cancer Cells through Combined Targeting of HMGCS1 and MEK Pathway
Sheng Zhou, Huanji Xu, Qiulin Tang, Hongwei Xia, Feng Bi
Molecular Cancer Therapeutics.2020; 19(1): 135.     CrossRef
Repurposed Drugs Trials by Cancer Type
Joseph C. Murray, Benjamin Levy
The Cancer Journal.2019; 25(2): 127.     CrossRef
Diverse Stakeholders of Tumor Metabolism: An Appraisal of the Emerging Approach of Multifaceted Metabolic Targeting by 3-Bromopyruvate
Saveg Yadav, Shrish Kumar Pandey, Yugal Goel, Mithlesh Kumar Temre, Sukh Mahendra Singh
Frontiers in Pharmacology.2019;[Epub]     CrossRef
Therapeutic effects of statins against lung adenocarcinoma via p53 mutant-mediated apoptosis
Cheng-Wei Chou, Ching-Heng Lin, Tzu-Hung Hsiao, Chia-Chien Lo, Chih-Ying Hsieh, Cheng-Chung Huang, Yuh-Pyng Sher
Scientific Reports.2019;[Epub]     CrossRef
Drug Repurposing of Metabolic Agents in Malignant Glioma
Corinna Seliger, Peter Hau
International Journal of Molecular Sciences.2018; 19(9): 2768.     CrossRef
The Effect of Statin Added to Systemic Anticancer Therapy: A Meta-Analysis of Randomized, Controlled Trials
Hyun Jang, Hyeong Kim, Jung Kim, Jin Lee
Journal of Clinical Medicine.2018; 7(10): 325.     CrossRef
Statin therapy in the treatment of active cancer: A systematic review and meta-analysis of randomized controlled trials
Mohammed A. M. Farooqi, Nikita Malhotra, Som D. Mukherjee, Stephanie Sanger, Sukhbinder K. Dhesy-Thind, Peter Ellis, Darryl P. Leong, Robert M. Lafrenie
PLOS ONE.2018; 13(12): e0209486.     CrossRef
Synergistic effect of receptor-interacting protein 140 and simvastatin on the inhibition of proliferation and survival of hepatocellular carcinoma cells
Kun Xia, Panpan Zhang, Jian Hu, Huan Hou, Mingdi Xiong, Junping Xiong, Nianlong Yan
Oncology Letters.2018;[Epub]     CrossRef